Merck (MRK) Short term Debt (2009 - 2026)

Merck (MRK) has reported Short term Debt for 18 consecutive years, with $2.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short term Debt rose 97.0% year-over-year to $2.8 billion in Q2 2026; TTM through Jun 2026 was $2.8 billion, a 97.0% increase from a year earlier, with the FY2025 full-year figure at $2.6 billion, down 2.27% from the prior year.
• Short term Debt was $2.8 billion for Q2 2026 at Merck, up from $2.4 billion in the prior quarter.
• Over five years, Short term Debt peaked at $3.1 billion in Q3 2024 and troughed at $887.0 million in Q3 2023.
• A 5-year average of $2.2 billion and a median of $2.5 billion in 2025 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt sank 83.34% in 2022 and soared 255.02% in 2024, its largest moves.
• Over 5 years, Short term Debt stood at $1.9 billion in 2022, then retreated by 29.5% to $1.4 billion in 2023, then jumped by 93.08% to $2.6 billion in 2024, then declined by 2.27% to $2.6 billion in 2025, then increased by 9.12% to $2.8 billion in 2026.
• The last three Short term Debt figures came in at $2.8 billion (Q2 2026), $2.4 billion (Q1 2026), and $2.6 billion (Q4 2025), per Business Quant data.